Assess whether to resubmit, meet, or pause the program (5df186)

SITUATION A 505(b)(2) program relying on literature plus a bridging study has scientific-advice briefing book in hand following a competitor label that just got a narrower indication. Labeling negotiator must determine whether to resubmit, meet, or pause the program for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose To resubmit, meet,, Pause the program using scientific-advice briefing book after a competitor label that just got a narrower indication. The question on that file is whether to resubmit, meet, or pause the program.

HYPOTHESES TO TEST 1. Labeling negotiator can defend To resubmit, meet, from scientific-advice briefing book after a competitor label that just got a narrower indication in a Pharma & Life Sciences challenge. 2. Labeling negotiator cannot defend To resubmit, meet, from scientific-advice briefing book; Pause the program is what the extract actually supports after a competitor label that just got a narrower indication. 3. A competitor label that just got a narrower indication never reached the population in scientific-advice briefing book — reopen intake, do not close to resubmit, meet, or. 4. Two facts in scientific-advice briefing book after a competitor label that just got a narrower indication conflict for labeling negotiator; hold this CMC and Development Pathways file.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 3. Check whether scientific-advice briefing book supports the labeled claim labeling negotiator would keep. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against a competitor label that just got a narrower indication and write the one fact that would move to resubmit, meet, or for labeling negotiator.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after a competitor label that just got a narrower indication). The follow-on CMC and Development Pathways action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in scientific-advice briefing book, then the action for labeling negotiator - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Named option among To resubmit, meet,, Pause the program and the fact that kills the others - Owner and next date for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study